Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) Income from Continuing Operations (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Income from Continuing Operations for 7 consecutive years, with 194635000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 27.21% to 194635000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 704503000.0 through Dec 2025, down 33.87% year-over-year, with the annual reading at 732938000.0 for FY2025, 34.89% down from the prior year.
  • Income from Continuing Operations hit 194635000.0 in Q4 2025 for BridgeBio Pharma, down from 184982000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 19053000.0 in Q1 2024 to a low of 267389000.0 in Q4 2024.
  • Historically, Income from Continuing Operations has averaged 155436950.0 across 5 years, with a median of 163216500.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: surged 86.59% in 2024 and later tumbled 640.71% in 2025.
  • Year by year, Income from Continuing Operations stood at 180566000.0 in 2021, then grew by 19.62% to 145130000.0 in 2022, then tumbled by 32.37% to 192106000.0 in 2023, then crashed by 39.19% to 267389000.0 in 2024, then increased by 27.21% to 194635000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for BBIO at 194635000.0 in Q4 2025, 184982000.0 in Q3 2025, and 183758000.0 in Q2 2025.